Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » CanForum 2024 – A Rare Cancer Moonshot

CanForum 2024 – A Rare Cancer Moonshot

  • August 21, 2024

NECA Nurse Educator/Project Officer Kahlia Wolsley and NET Patient Roxanne Coghlan were honoured to be invited by Rare Cancers Australia to represent NECA at the CanForum24 this year, which was held at the Australian Parliament House, 20th August 2024.

CanForum24 brought together patients, leaders, and experts in cancer to discuss bold, and innovative approaches and ideas in the hope to create action to improve equity of outcomes and experiences for every person diagnosed with cancer in this country.

The sessions throughout the forum focused on 3 topics: a better world for rare, no one left behind and the countdown is on, with speakers such as Professor Georgina Long AO, Professor Dorothy Keefe PSM, Mike Stephens, Professor Michelle Haber, Professor David Thomas and Professor Kim Alexander with many more attending for panel discussions. Lived experiences were also shared by patient advocates throughout the day highlighting the need for equity for individual’s with rare cancers.

During the forum Hon Mark Butler launched the report ‘A Rare Cancer Moonshot: Equity for everyone with cancer’.

This report sets an ambitious target for Australia: to achieve greater than 90% five-year survival for everyone diagnosed with cancer, and for true equity of experience by 2035. The report identifies six priorities to implement within the next year to be able to achieve this vision:

  1. Government to deliver recommendations of the Senate Inquiry into Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer
  2. Develop and implement the National Genomics Strategy
  3. Reform Australia’s Health Technology Assessment (HTA) with an immediate priority of establishing frameworks that assess pan-tumour treatment applications
  4. Invest in novel clinical trials and telehealth
  5. Ensure rare and less common cancers are represented within the National Cancer Data Framework
  6. Prioritise research funding with a focus on translation into clinical practice.

NECA will continue to work with the Australian Government, key stakeholders and patients to ensure the Governments own recommendations from the Senate Inquiry are implemented. Should you wish to lend your voice and advocate for improved care for NET Patients please learn more here.

Share this post

Recent posts

Radio National Interview: Changing Australia June 2025

June 30, 2025

Adelaide NET Patient Forum 2025

June 24, 2025

CNSA & ICCN 2025 Congress: Global Voices, Local Actions

June 24, 2025

Announcing our First Patient Ambassador – Cassie Miller

June 17, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousTeam Janine completes City2Surf and raises over $9,000 for NECA
NextNeuroEndocrine Cancer Australia Celebrates Groundbreaking PBS Recommendation of Life-Changing Treatment for Von Hippel-Lindau (VHL) Patients.Next

Related Posts

Radio National Interview: Changing Australia June 2025

Rare cancers can be extremely difficult to diagnose, and it can take years of misdiagnoses before a culprit is found and patients get adequate treatment.

Adelaide NET Patient Forum 2025

Pictured – DR Ria Joseph, Dr Chad Han, A/Prof Gabby Cehic, Meredith Cummins, Dr Rebekah Chew, Jessica Mercurio and Dr Rahul Solanki Thank you to

CNSA & ICCN 2025 Congress: Global Voices, Local Actions

NECA proudly attended the CNSA & ICCN 2025 Annual Congress, held at the Adelaide Convention Centre from 18–21 June 2025. This landmark event was a

Announcing our First Patient Ambassador – Cassie Miller

NeuroEndocrine Cancer Australia is proud to welcome Cassie Miller from Queensland as our very first official Patient Ambassador. Cassie was 36 when she was diagnosed

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin